Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (941)	8/30/1999 2:47:00 PM
From: Gordon James	Respond to of 2515

Tuck, No need to be apologetic, we're all here to learn things we don't know. I'll admit to some early confusion myself as these C225 trials have rolled out, trying to square company statements with the specifics of the studies announced. To me, the statements made back in March couldn't begin to be squared until we got a trial like the PhaseII refractory study recently announced. The parameters of the PhaseIII trials do not support the kind of submission timeframe the company hinted at back in March, but now we're closer. Cheers, Gordon